Deferasirox
Showing 26 - 50 of 114
Thalassemia, Beta Trial in Karachi (Hydroxyurea and Thalidomide)
Completed
- Thalassemia, Beta
- Hydroxyurea and Thalidomide
-
Karachi, Sindh, PakistanChildren's Hospital Karachi
Nov 23, 2023
Aplastic Anemia Trial in Moscow (ICL670, Chelation, No chelation)
Terminated
- Aplastic Anemia
- ICL670
- +2 more
-
Moscow, Russian FederationNovartis Investigative Site
Jul 8, 2019
Transfusion-dependent Iron Overload Trial in Worldwide (Deferasirox)
Completed
- Transfusion-dependent Iron Overload
- Deferasirox
-
Adelaide, Australia
- +97 more
Feb 8, 2020
Different Risk Factors on Growth Parameters of Thalassemic
Not yet recruiting
- Thalassemia Major
- serum ferritin and AST
- (no location specified)
Mar 29, 2022
Beta Thalassemia Major Trial in Tirana (Emeramide)
Completed
- Beta Thalassemia Major
-
Tirana, AlbaniaUniversity Hospital Center "Mother Theresa" Tirana
Aug 20, 2021
Iron Overload, Oxidative Stress, Thalassemia Major Trial in Bani Suwayf, Mecca (Omega 3, Nigella Sativa Oil, Hydroxyurea)
Completed
- Iron Overload
- +2 more
- Omega 3
- +5 more
-
Banī Suwayf, Egypt
- +3 more
Jan 25, 2021
Myelodysplastic Syndrome Trial in Liege (Bone marrow aspirate, Deferasirox)
Terminated
- Myelodysplastic Syndrome
- Bone marrow aspirate
- Deferasirox
-
Liege, BelgiumNovartis Investigative Site
Jul 24, 2018
Low and Int 1-risk Myelodysplastic Syndrome Trial in Worldwide (Deferasirox DFX, DT, Erythropoietin alpha, Deferasirox DFX, FCT)
Completed
- Low and Int 1-risk Myelodysplastic Syndrome
- Deferasirox DFX, DT
- +2 more
-
Oran, Algeria
- +29 more
Oct 4, 2018
Postmenopausal Osteoporosis Trial in Suzhou (Deferasirox and calcium-vitamin D3, Calcium-vitamin D3)
Unknown status
- Postmenopausal Osteoporosis
- Deferasirox and calcium-vitamin D3
- Calcium-vitamin D3
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
May 13, 2018
Liver Fibrosis in Sickle Cell Disease
Completed
- Sickle Cell Disease
- Liver transient elastography (Fibroscan)
- +2 more
-
Miami, FloridaUniversity of Miami
May 21, 2021
MDS Trial in Toronto (Deferasirox + Azacitidine, Azacitidine)
Terminated
- Myelodysplastic Syndromes
- Deferasirox + Azacitidine
- Azacitidine
-
Toronto, Ontario, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre
Apr 24, 2018
Thalassemia in Children Trial in Alexandria (Benson's Relaxation technique, Music therapy)
Active, not recruiting
- Thalassemia in Children
- Benson's Relaxation technique
- Music therapy
-
Alexandria, Egyptthe Hematology Out-Patient Clinic of the Children's University H
Feb 13, 2023
Erythroid Response in Myelodysplasia Undergoing Chelation
Unknown status
- Myelodysplasia
- +2 more
-
Alessandria, AL, Italy
- +19 more
Jul 29, 2019
Breast Cancer, Iron Overload, Leukemia Trial in Minneapolis (deferasirox)
Terminated
- Breast Cancer
- +7 more
- deferasirox
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Dec 3, 2017
MDS Trial in Belgium, France (Deferasirox, Vitamin D and Azacitidine)
Unknown status
- MDS
- Deferasirox, Vitamin D and Azacitidine
-
Gent, Belgium
- +14 more
Jan 9, 2018
Satisfaction in ß-Thalassemia Patients Receiving Deferasirox
Unknown status
- β-thalassemia
- The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It
-
Assiut, EgyptAssiut University Hospital
Nov 27, 2017
Beta-thalassemia, MDS, Fanconi Syndrome Trial in United States (Deferasirox)
Completed
- Beta-thalassemia
- +4 more
- Deferasirox
-
Oakland, California
- +5 more
Aug 17, 2017
Erythrocyte Transfusion, Beta-Thalassemia Trial in Worldwide (Luspatercept, Placebo)
Completed
- Erythrocyte Transfusion
- Beta-Thalassemia
- Luspatercept
- Placebo
-
Los Angeles, California
- +72 more
Jan 21, 2022
MDS Trial in Belgium
Unknown status
- Myelodysplastic Syndromes
-
Bonheiden, Antwerpen, Belgium
- +20 more
Aug 9, 2019
Thalassemia (Transfusion Delendent) Trial (deferasirox)
Withdrawn
- Thalassemia (Transfusion Delendent)
- deferasirox
- (no location specified)
Apr 19, 2017
Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD Trial (Deferasirox)
Withdrawn
- Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
- Deferasirox
- (no location specified)
Apr 19, 2017
ß-thalassemia Major Trial (Deferasirox)
Withdrawn
- β-thalassemia Major
- Deferasirox
- (no location specified)
Apr 19, 2017
MDS, Transfusion Dependent Iron Overload Trial in Berlin (ICL670/Deferasirox)
Completed
- Myelodysplastic Syndromes
- Transfusion Dependent Iron Overload
-
Berlin, GermanyNovartis Investigative Site
May 30, 2017
Pulmonary Hypertension Risk in Beta Thalassemia Major Children
Completed
- Thalassemia in Children
- +2 more
- blood sample
- Tricuspid regurge velocity
-
Assiut, EgyptAssiut University
Aug 26, 2019